Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490490 · ClinicalTrials.gov registry record · Phase 2
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00490490: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00490490 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00490490, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the response rate of patients with relapsed or refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma to Iodine-131 (I-131) tositumomab (Bexxar) therapy plus local palliative radiation therapy (XRT).
Interventions
- DRUG Potassium Iodide (KI)
- DRUG Bexxar (tositumomab)
- PROCEDURE External beam radiotherapy (XRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00490490
The ClinicalTrials.gov registry entry for NCT00490490 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Potassium Iodide (KI) is the first listed.
NCT00490490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00490490 about?
NCT00490490 is a clinical study titled "Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy". The purpose of the study is to assess the response rate of patients with relapsed or refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma to Iodine-131 (I-131) tositumomab (Bexxar) therapy plus local palliative radiation therapy (XRT).
What is the current status of trial NCT00490490?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2007-01. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00490490?
The interventions under investigation include: Potassium Iodide (KI) (DRUG), Bexxar (tositumomab) (DRUG), External beam radiotherapy (XRT) (PROCEDURE).
Who is sponsoring clinical trial NCT00490490?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.